OPEN ACCESS Freely available online

ISSN: 2167-7956
Journal of Biomolecular Research & Therapeutics

Perspective

Drug Delivery Systems for Nanoparticles in Cancer Therapy

Saji Mohanty*

Department of Bioengineering , Chungnam National University, Yuseoung-gu, Korea

DESCRIPTION

Carcinoma belongs to the most serious diseases, accounting for worldwide. Despite significant breakthroughs in pharmaceutical drugs these treatments are ineffective in eradicating cancer. Based on the compositions of multiple nanoparticles, nanomaterial's has the ability to treat cancer. Solid lipid nanoparticles and polymeric nanoparticles are the most researched and effective anticancer Drug Delivery Systems (DDS). Liposomes are promising DDS because to their unique qualities which include heavy drug entrapment efficiency, biocompatibility, inexpensive and scalability. Nevertheless their usage is limited because to lipids oxidation sensitivity, volatility, drug burst release and reduced surface treatment. Microparticles exhibit numerous chemical alterations with monomers, high stability and sustained release but their limitations for biomedical application include restricted dosage form and polymers toxicity.

Cancer is a deadly disease and a major threat to public health. This can damage any organ in the body and is characterized by unregulated cell development and division. Several gene mutations, regulatory proteins are dysregulated, resulting in uncontrolled tumor development. Yet the external microenvironment also plays an important role in cancer formation and progression. In treatment for cancer various tactics are used each of which has a set of benefits as well as disadvantages. Surgery, chemotherapeutic and radiotherapy are examples of traditional therapeutic techniques that are widely employed in clinical practice. These treatments are inefficient in totally eradicating cancer. High-intensity irradiation and surgical procedures can lead to tissue diseases, inflammation and oxidative damage to DNA in healthy cells, culminating in metastasis. Such features have piqued the interest of leading experts on cancer treatments and diagnostics. NPs improve the water solubility of hydrophilic anti-cancer drugs, extending sustained release within the body and allowing for building delivery of the medicinal contents by preventing non-tumor-specific concentration of the medication in healthy tissues. It have a large and an effective DDS, making them an appealing drug discovery system for chemo preventive detection and therapy. Vesicles, microcapsules, polysaccharides, inorganic NPs, and nano gels are among the many diverse Nanoparticle systems used as carriers for the delivery of medicines, genomes, enzymes, peptide and imaging agents to tumour sites. Because of their high success, polymers and liposome are the most efficient DDSs.

Vesicles are fatty plumes with a lipids phospholipid bilayer made up of both hydrophobic and lipid soluble lipid molecules. Natural or synthesized lipid membranes make up the lipid membranes. Other lipids such as cholesterol are employed in the formulation of NPs with greater flexibility which leads to greater bio stability and permeation throughout the body. Furthermore the circulation period of PEGylated or stealth liposomes can be increased by altering the surface with Propylene Glycol (PEG). The benefits of lipid nanoparticles are related to microencapsulation into both hydrophobic as well as hydrophilic compartments which creates a dynamic interface with various protein targets to aggressively target cancer cells. Vesicles have cytocompatibility, biocompatible, tailored delivery of drugs capability and large-scale manufacture for use. To stabilize the nanoparticle formation a mixture of triglycerides is occasionally utilized to form the outer surface of these mixed NPs. The individual lipids may self-assemble with its amphiphilic facing the aqueous layer, but and the rest forms a complicated lipid-PEG structure. The quantity of lipids influences the production of microspheres and lipid membranes during the construction of such a complicated pattern. The low lipid content inhibits such particle production.

Correspondence to: Saji Mohanty, Department of Bioengineering, Chungnam National University, Yuseoung-gu, Korea, E-mail: mohanty@gmail.com

Received: 03-Mar-2023, Manuscript No. BOM-23-20734; **Editor assigned:** 06-Mar-2023, Pre QC No. BOM-23-20734(PQ); **Reviewed:** 22-Mar-2023, QC No. BOM-23-20734; **Revised:** 29-Mar-2023, Manuscript No. BOM-23-20734 (R); **Published:** 05-Apr-2023, DOI: 10.35248/2167-7956.23.12.278.

Citation: Mohanty S (2023) Drug Delivery Systems for Nanoparticles in Cancer Therapy. J Biol Res Ther. 12:278.